Possible Therapeutic Effects of Adjuvant Quercetin Supplementation Against Early-Stage COVID-19 Infection: A Prospective, Randomized, Controlled, and Open-Label Study
Francesco Di Pierro,Giuseppe Derosa,Pamela Maffioli,Alexander Bertuccioli,Stefano Togni,Antonella Riva,Pietro Allegrini,Amjad Khan,Saeed Khan,Bilal Ahmad Khan,Naireen Altaf,Maria Zahid,Ikram Din Ujjan,Roohi Nigar,Mehwish Imam Khushk,Maryam Phulpoto,Amanullah Lail,Bikha Ram Devrajani,Sagheer Ahmed
DOI: https://doi.org/10.2147/IJGM.S318720
IF: 2.145
2021-06-09
International Journal of General Medicine
Abstract:Francesco Di Pierro, 1, 2 Giuseppe Derosa, 3, 4 Pamela Maffioli, 4 Alexander Bertuccioli, 5 Stefano Togni, 6 Antonella Riva, 6 Pietro Allegrini, 6 Amjad Khan, 7, 8 Saeed Khan, 9 Bilal Ahmad Khan, 9 Naireen Altaf, 9 Maria Zahid, 9 Ikram Din Ujjan, 10 Roohi Nigar, 11 Mehwish Imam Khushk, 10 Maryam Phulpoto, 11 Amanullah Lail, 12 Bikha Ram Devrajani, 13 Sagheer Ahmed 14 1 Scientific & Research Department, Velleja Research, Milan, Italy; 2 Digestive Endoscopy, Fondazione Poliambulanza, Brescia, Italy; 3 Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy; 4 Laboratory of Molecular Medicine, University of Pavia, Pavia, Italy; 5 Department of Biomolecular Sciences (DISB), University of Urbino, Urbino, Italy; 6 Indena Research and Development Department, Milan, Italy; 7 Chemistry Research Laboratory, Department of Chemistry, University of Oxford, Oxford, UK; 8 University of Health Sciences, Lahore, Pakistan; 9 Department of Molecular Pathology, Dow International Medical College, Dow University of Health Sciences, Karachi, Pakistan; 10 Department of Pathology, Liaquat University of Medical & Health Sciences, Jamshoro, Sindh, Pakistan; 11 Department of Obstetrics and Gynaecology, Liaquat University of Medical & Health Sciences, Jamshoro, Sindh, Pakistan; 12 Department of Paediatric Dow International Medical College, Dow University of Health Sciences, Karachi, Pakistan; 13 Department of Medicine, Liaquat University of Medical & Health Sciences, Jamshoro, Sindh, Pakistan; 14 Shifa College of Pharmaceutical Sciences, Shifa Tameer-e-Millat University, Islamabad, Pakistan Correspondence: Francesco Di Pierro Scientific & Research Department, Velleja Research, Milan, Italy Tel +39 023510848 Fax +39 023 511894 Email Background: Quercetin, a well-known naturally occurring polyphenol, has recently been shown by molecular docking, in vitro and in vivo studies to be a possible anti-COVID-19 candidate. Quercetin has strong antioxidant, anti-inflammatory, immunomodulatory, and antiviral properties, and it is characterized by a very high safety profile, exerted in animals and in humans. Like most other polyphenols, quercetin shows a very low rate of oral absorption and its clinical use is considered by most of modest utility. Quercetin in a delivery-food grade system with sunflower phospholipids (Quercetin Phytosome ® , QP) increases its oral absorption up to 20-fold. Methods: In the present prospective, randomized, controlled, and open-label study, a daily dose of 1000 mg of QP was investigated for 30 days in 152 COVID-19 outpatients to disclose its adjuvant effect in treating the early symptoms and in preventing the severe outcomes of the disease. Results: The results revealed a reduction in frequency and length of hospitalization, in need of non-invasive oxygen therapy, in progression to intensive care units and in number of deaths. The results also confirmed the very high safety profile of quercetin and suggested possible anti-fatigue and pro-appetite properties. Conclusion: QP is a safe agent and in combination with standard care, when used in early stage of viral infection, could aid in improving the early symptoms and help in preventing the severity of COVID-19 disease. It is suggested that a double-blind, placebo-controlled study should be urgently carried out to confirm the results of our study. Keywords: SARS-CoV-2, infectious diseases, coronavirus, pneumonia, botanicals, Phytosome ® The current pandemic, known as coronavirus disease 2019 (COVID-19) triggered by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is provoking devastating health, psychological and financial consequences worldwide. 1–3 Although several vaccines have been developed, due to limitation in their manufacturing and distribution capacities, the desired globally "herd immunity" still appears to be a distant mirage. In addition, the constant mutations in SARS-CoV-2 put the effectiveness of these vaccination campaigns at serious risk regardless of its speed. 4 The current antivirus agents being used, including hydroxychloroquine, ivermectin, lopinavir/ritonavir, have not shown any conclusive benefits. 5 New possible treatments that are safe, affordable, and worldwide available targeting the SARS-CoV -Abstract Truncated-
medicine, general & internal